Septo-hippocampal system: target for substituted benzamides.
Effects of the substituted benzamide, and of oxiperomide on DA receptors and on Da-related behaviors were the object of the study. The benzamides were practically inactive on DA-sensitive adenylate cyclase and on in vitro [3H] spiperone binding (in the absence of sodium ions). However, all of them inhibited in vivo [3H] spiperone binding in various rat brain regions; this in vivo effect was especially apparent in hippocampus and septum. In frontal cortex, the benzamides (with the exception of metoclopramide) produced only a partial inhibition of [3H] spiperone binding. Such inhibition also occurred in the striatum with sulpiride and tiapride. The results suggest that substituted benzamides are DA antagonists due to their ability to inhibit in vivo [3H] spiperone binding. The lack of agreement between in vivo and in vitro tests is also discussed.
D000262:Adenylyl Cyclases / Q000378:metabolism; D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001549:Benzamides / Q000494:pharmacology*; D001667:Binding, Competitive; D001921:Brain / Q000187:drug effects*; D003342:Corpus Striatum / Q000378:metabolism; D006624:Hippocampus / Q000187:drug effects*; D006801:Humans; D008297:Male; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects*; D013134:Spiperone / Q000378:metabolism; D013239:Stereotyped Behavior / Q000187:drug effects
D001549:Benzamides; D011954:Receptors, Dopamine; D013134:Spiperone; D000661:Amphetamine; D000262:Adenylyl Cyclases; D001058:Apomorphine